Core Viewpoint - The company, Fuhong Hanlin (02696.HK), has announced that its self-developed Hanbeitai® (Bevacizumab Injection) has had its biological product license application accepted by the U.S. Food and Drug Administration (FDA) [1] Group 1: Product and Indications - The application involves several indications, including: 1. Metastatic colorectal cancer 2. First-line treatment of unresectable locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel 3. Recurrent adult glioblastoma 4. Treatment of metastatic renal cell carcinoma in combination with interferon α 5. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 6. Treatment of persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel and cisplatin, or paclitaxel and topotecan [1]
复宏汉霖：贝伐珠单抗注射液的生物制品许可申请获美国食品药品管理局受理